Related references
Note: Only part of the references are listed.Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
H. S. Rugo et al.
ANNALS OF ONCOLOGY (2018)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)
F. Cardoso et al.
BREAST (2017)
Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
John F. R. Robertson et al.
LANCET (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Ann H. Partridge et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Lapatinib plus capecitabine versus capecitabine alone for HER2+(ErbB2+) metastatic breast cancer: quality-of-life assessment
Xiaolei Zhou et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
A small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data
Marco Bonetti et al.
STATISTICS IN MEDICINE (2009)
Share Paper
